Multiple Overimputation to Address Missing Data and Measurement Error: Application to HIV Treatment During Pregnancy and Pregnancy Outcomes by Bengtson, Angela M. et al.
Multiple overimputation to address missing data and 
measurement error: application to HIV treatment during 
pregnancy and pregnancy outcomes
Angela M. Bengtson1, Daniel Westreich1, Patrick Musonda2, Audrey Pettifor1, Carla 
Chibwesha3, Benjamin H. Chi3,4, Bellington Vwalika2, Brian W. Pence1, Jeffrey SA. 
Stringer3, and William C. Miller1,5
1Department of Epidemiology, University of North Carolina-Chapel Hill
2University of Zambia, Lusaka, Zambia
3Department of Obstetrics and Gynecology, University of North Carolina-Chapel Hill
4Centre for Infectious Disease Research in Zambia
5Department of Medicine, University of North Carolina-Chapel Hill.
Abstract
Background—Investigations of the association of combination antiretroviral therapy (ART) with 
pregnancy outcomes often rely on routinely collected clinical data, which are prone to missing 
data and measurement error. Measurement error in gestational age may bias the relationship 
between combination ART and gestational age-based outcomes.
Methods—We demonstrate the use of multiple overimputation to address missing data and 
measurement error in gestational age. Using routinely collected clinical data from public health 
facilities in Lusaka, Zambia, we multiply imputed missing data and multiply overimputed 
observed values of gestational age. Poisson models with robust variance estimators were used to 
estimate risk ratios (RRs) for the associations of duration of combination ART with small for 
gestational age (SGA) and preterm birth. We compared results from a complete-case analysis, 
using multiple imputation to address missing data only, and using multiple overimputation to 
address missing data and measurement error.
Results—In the complete-case analysis, there was no evidence of an association between 
duration of combination ART and SGA or preterm birth. When we performed multiple 
overimputation, RRs for SGA moved past the null, but remained imprecise. For preterm birth, RRs 
for 9-32 weeks of combination ART moved away from the null as the variance due to 
measurement error increased.
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Conclusion—When we used multiple overimputation to account for measurement error and 
missing data, we observed an increased risk of preterm birth with longer duration of combination 
ART. Future analyses examining associations between combination ART and pregnancy outcomes 
should consider using multiple overimputation to address measurement error in gestational age.
Introduction
In 2013 the WHO recommended lifetime combination antiretroviral therapy (ART) for all 
HIV-infected pregnant women in countries with a generalized HIV epidemic.(1) When taken 
consistently during pregnancy and breastfeeding, combination ART reduces the risk of 
mother-to-child HIV transmission to <5%.(2) However, the effect of combination ART on 
fetal growth and length of gestation remains controversial; its use during pregnancy has been 
associated with preterm birth (3, 4) and low infant birthweight (LBW(5) in Europe and the 
United States.(6) In resource-limited settings, combination ART use during pregnancy has 
also been associated with an increased risk of preterm birth (7), LBW (8) and small for 
gestational age (SGA).(9)
The impact of combination ART on pregnancy outcomes is of great concern in sub-Saharan 
Africa, where HIV prevalence remains high among women of reproductive age and lifetime 
combination ART initiation during pregnancy is rapidly being scaled up.(10) With nearly 13 
million people on combination ART globally, the need to understand combination ART's 
association with pregnancy outcomes is critical.(11) In resource-limited settings, 
investigations of combination ART's association with pregnancy outcomes often rely on 
routinely collected clinical data.(9) Clinical data provides an important source of 
information for monitoring pregnancy outcomes of HIV-infected women, but are typically 
not collected for research purposes. Routinely collected clinical data are consequently often 
plagued by missing data and measurement error.(12)
Missing data and measurement error in gestational age may introduce bias when evaluating 
the relationship between combination ART and gestational age-based outcomes like preterm 
birth and SGA. Gestation age dating based on last menstrual period (LMP) may include 
error due to natural variation in menstrual cycle length (and thus timing of ovulation, relative 
to LMP), errors in recall or missing LMP dates.(13) Inaccurate LMP dates may be more 
common among women in the developing world, where malnutrition, high fertility rates and 
longer breastfeeding duration may result in women not resuming regular menstrual cycles 
before becoming pregnant again.(14) Menstrual abnormalities are common in HIV-infected 
women, which may further limit the reliability of LMP dating (15) and have implications for 
our understanding of combination ART's association with preterm birth and SGA.
To assess the impact of bias from missing data and measurement error in GA on the 
associations of duration of combination ART with SGA and preterm birth, we demonstrate 
the use of multiple overimputation. We describe multiple overimputation and illustrate its 
use as applied to routinely collected clinical data from public healthcare facilities in Lusaka, 
Zambia. We end with a discussion of our results and an evaluation of whether MOs 
assumptions are likely met in our data.
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Methods
Multiple overimputation
Multiple overimputation is a convenient approach to address missing data and measurement 
error simultaneously. Practical and technical details for multiple overimputation has been 
described elsewhere.(19-23) Our goal is to illustrate the use of multiple overimputation to 
address missing data and measurement error in gestational age. Briefly, multiple 
overimputation addresses missing data in the same way as multiple imputation: missing 
values are multiply imputed based on observed covariates. Observed, but mismeasured, 
values are handled slightly differently. Mismeasured values are overimputed (replaced) with 
multiply imputed values based on observed covariates, with an additional step: observed 
mismeasured values are used to create observation-level Bayesian priors for the imputation 
model.(19) The goal of specifying observation-level Bayesian priors is to incorporate prior 
knowledge (in the form of the observed mismeasured value), as well as appropriate 
uncertainty, about an observed variable's true value into the imputation model.(19) 
Specifying observation-level Bayesian priors involves two parts: specifying the mean of the 
prior distribution and the variance due to measurement error. Additional details about 
specifying observation-level priors, multiple overimputation, and its assumptions are 
available in eAppendix 1.
Data Analysis
We provide an illustrative example of multiple overimputation to address measurement error 
in gestational age when examining the association of duration of combination ART with 
SGA and preterm birth. Duration of combination ART during pregnancy may affect length 
of gestational or fetal growth, (26) leading to an increased risk of preterm birth or SGA.(7, 
9) In order to better understand the relationship between duration of combination ART with 
SGA and preterm birth, accurately measuring gestational age is critical. Data for the present 
retrospective cohort analysis come from the Zambia Electronic Perinatal Record System 
(ZEPRS), which has collected routine maternity and HIV clinical information in 24 public 
facilities in Lusaka, Zambia since 2007. Clinics in ZEPRS see a high volume of patients and 
errors in in remembering or recording LMP dates are common. Therefore measurement error 
within each week of gestational age was considered likely to be normally distributed. The 
goal of our illustrative example was to assess whether associations for duration of 
combination ART with SGA and preterm birth changed under differing assumptions about 
measurement error in gestational age.
Study population
Women who presented for antenatal care and delivered between January 1, 2009 and 
September 2, 2013 were included in the present analysis if they had a CD4 count of ≤350 
cells/uL, were not on combination ART at entry into antenatal care and delivered a singleton 
pregnancy at a public healthcare facility at ≥28 weeks gestation (fetal viability cut-off in 
Zambia). Women with chronic conditions such as known heart disease, hypertension, and 
diabetes were excluded since they have poorer pregnancy outcomes (27, 28) and may be 
more likely to seek antenatal care earlier due to their preexisting conditions. A related 
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analysis used a similar study population, but evaluated LBW as an outcome(29). Ethical 
approval for the analysis of routinely collected clinical data was obtained from the 
University of Zambia Biomedical Research Ethics Committee (Lusaka, Zambia) and the 
University of North Carolina, Chapel Hill (Chapel Hill, NC).
Definitions
For the present analysis, SGA was considered the primary outcome in order to evaluate fetal 
growth adjusted for length of gestation. SGA was defined as birthweight below the 10th 
percentile for each week of gestational age at birth (weeks 28-41). The reference curve used 
to define SGA was based on fetal weight and adjusted to account for lower overall 
birthweights in a Zambian population.(30) This method has previously been shown to 
reliably classify SGA infants, in comparison to more complex customized reference curves.
(30) Preterm birth (delivery at <37 weeks gestation) was considered as a secondary outcome. 
The exposure of interest was duration of combination ART before delivery, measured in 
completed weeks and assessed at 32 weeks gestation. Duration of combination ART during 
pregnancy is intrinsically linked to length of gestation. Consequently, longer duration of 
treatment may appear protective against preterm birth simply by being a marker of longer 
gestation. To mitigate the dependency between duration of treatment and duration of 
gestation, and allow the majority of women to complete their exposure duration before 
delivery, we assessed combination ART duration at 32 weeks. Duration of combination ART 
was categorized into four groups: never initiated or did not initiate by 32 weeks gestation 
(referent), 1-8 weeks, or 9-32 weeks. Category cut-points were based on the functional form 
of the relationship between the exposure and outcome, as well as clinical considerations to 
approximately correspond with early and mid-to-late pregnancy.
We identified likely confounders using directed acyclic graphs (31, 32) and included age, 
baseline body mass index (BMI), baseline CD4 count, baseline hemoglobin, education, 
intermittent presumptive therapy (IPT) for malaria, parity, reported previous preterm birth 
(<37 weeks gestation), syphilis screening/treatment, self-reported tuberculosis status and 
number of antenatal care visits. Number of antenatal care visits and education were used as 
proxies for health seeking behavior.(33) The functional form of the relationship between 
continuous confounders and outcome was assessed and confounders were modeled using 
restricted quadratic splines.(34) All confounders were included in multivariable models. 
Information on viral load, WHO clinical stage, antiretroviral adherence and drug regimen 
was not available.
Assessment of Measurement Error in Gestational Age
As is common practice in many resource-limited settings, (35) gestational age was 
calculated by last menstrual period (LMP) for pregnancies less than 20 weeks at time of 
enrollment into antenatal care. For those ≥20 weeks at enrollment, both LMP and 
symphysis-fundal height were used. If these two methods yielded gestational ages within 3 
weeks of each other, the date based on the LMP was used. If not, the fundal height–derived 
gestational age was used.
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We assessed the presence and direction of measurement error in observed gestational age 
values by comparing the mean birthweight for each week of gestational age at birth to a 
reference curve adjusted to a Zambian population.(30) For each observed week of 
gestational age at birth, we determined the expected gestational age value by finding the 
smallest absolute difference in mean birthweight among reference curve values. For 
example, if the mean birthweight for infants born at observed gestational age 35 weeks was 
2,900 grams, based on reference value mean birthweights the gestational age was more 
likely to be 38 weeks. We repeated the same process for the 25th and 75th percentiles of 
weight to assess if the pattern of observed versus expected values was consistent across the 
birthweight distribution (Figure 1). The difference between observed and expected values of 
gestational age was used to account for the bias (ai) (or non-random nature) of the 
measurement error in gestational age.
To investigate the possibility of digit preference in measured birthweight values (which 
could affect expected gestational age values), we inspected histograms of birthweight for 
each week of gestational age (eAppendix 2). We attempted to account for digit preference in 
gestational age values by choosing estimates of bias (ai) between observed and expected 
gestational ages. Values of ai ranging from 4 to 0 weeks were used to account for both 
random and non-random measurement error across the distribution of gestational age 
(Figure 2).
Statistical Analyses
We used Poisson models with robust variance estimators to estimate risk ratios (RR) and 
95% confidence intervals (CIs),(36) due to lack of convergence of log-binomial models, for 
the associations of duration of combination ART with SGA and preterm birth in three 
separate analyses. First, we conducted a complete-case analysis using only the observed data 
(naïve-analysis). Second, we used multiple imputation to impute missing data for all 
confounders, the exposure and the GA as a continuous measure (used to define both 
outcomes). The imputation model included predictors of any missing data (not only missing 
GA), all confounders, the exposure and the outcome.(20) Third, we used multiple 
overimputation to impute missing confounder and exposure information and to overimpute 
GA. Due to the fact that the data arise from routine clinical care and not all women are under 
observation from a uniform time point in pregnancy, we note that reported effect estimates 
are interpretable as associations and not causal effects.
We conducted four sensitivity analyses. First, we conducted an analysis assuming only 
normal random measurement error in gestational age. Second, we included only women who 
delivered after 32 weeks of gestation. Third, to account for the possibility of measurement 
error in birthweight, we overimputed both gestational age and birthweight. Finally, we 
altered the specification of the imputation model and assessed whether results meaningfully 
changed.
Observation-level priors were specified for all measured values of gestational age. To 
account for non-random measurement error in the distribution of gestational age, we set each 
observation-level prior mean to the observed value of gestational age (wi) plus an estimate of 
the bias (ai) (eAppendix Table 1) in gestational age. Conditional on each observation-level 
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prior mean and observed covariates, measurement error was assumed to be random. 
Information on the degree of measurement error in gestational age in our data was not 
available. To be conservative we specified a range of variances due to measurement error, 
assuming that measurement error accounted for between 15% and 60% of the variance in 
gestational age, and was most likely 30%. Multiple overimputation was performed using the 
Amelia II package in R; all other statistical analyses were performed using SAS version 9.2 
(R Development Core Team Vienna, Austria; SAS Institute Inc. Cary, NC).(21)
Results
Among 50,765 HIV-infected pregnant women, 9,529 women met inclusion criteria for our 
study population. Of the 9,529 women included, 583 (8%) delivered SGA infants, 3,656 
(45%) delivered preterm infants and 108 (1%) delivered infants that were both preterm and 
SGA. Most women did not initiate combination ART by 32 weeks gestation (n=6,925, 77%; 
of these, 778 initiated combination ART at or after 32 weeks), 1415 (16%) women had 
between 1 and 8 weeks of combination ART by 32 weeks gestation and 611 (8%) had 
between 9 and 32 weeks of combination ART by 32 weeks gestation.
Missing data were common. Of the 9,529 women included, 1,399 (15%) were missing 
gestational age at birth. A SGA value could not be calculated for additional 733 women who 
had recorded gestational ages >41 weeks (SGA defined for weeks 28-41 only) or who were 
missing birthweight information (total missing SGA: n=2,132 (22%)). Only 5% (n=542) of 
women were missing exposure information due to not having a gestational age value at first 
antenatal care recorded. Overall, 6,625 (70%) of women were missing exposure, outcome or 
confounder information (Table 1).
Comparisons of birthweights for each week of gestational age with reference curve values 
suggested appreciable measurement error in gestational age. Among infants born preterm, 
observed gestational age was lower than expected, suggesting it was incorrectly specified as 
too early, perhaps due to the fact that women in this population may not be menstruating 
regularly. Among infants born at term, measurement error appeared to be more random (i.e. 
expected values randomly distributed around observed values) (Figure 1). Inspection of 
histograms of birthweight overall and by gestational age week revealed some digit 
preference at birthweight 3,000 grams.
Small for gestational age
There was no evidence of an association between combination ART and SGA in the naïve 
analysis: RR1.1 (95% CI 0.7, 1.9) for 9-32 weeks combination ART and RR 0.9 (95% CI 
0.6, 1.4) for =<8 weeks combination ART, by 32 weeks gestation (Figure 3). In the multiple 
overimputation analysis, when 30% of variance due to measurement error was assumed, 
receiving 9-32 weeks of combination ART was associated with RR 0.9 (95% CI 0.7, 1.21) 
and ≤8 weeks of combination ART was associated with RR 1.03 (95% CI 0.8, 1.3). As the 
amount of variance in gestational age due to measurement error increased, the joint 
distribution of gestational age and mean birthweight approached that of the reference curve 
values, suggesting that values for gestational age from the multiple overimputation analysis 
were closer to what might be expected, based on reference curve values (Figure 4).
Bengtson et al. Page 6
Epidemiology. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Preterm birth
Similarly, there was no evidence of an association between duration of combination ART 
and preterm birth in the naïve-analysis: RR 1.0 (95% CI 0.8, 1.2) for 9-32 weeks of 
combination ART and RR 1.0 (95%CI 0.9, 1.1) for ≤8 weeks of combination ART, by 32 
weeks. When 30% of variance due to measurement error was assumed, the risk of preterm 
birth increased with longer duration of combination ART: RR 1.2 (95% CI 1.0, 1.4) for 9-32 
weeks of combination ART and RR 1.0 (95% CI 0.9, 1.1) for ≤8 weeks of combination 
ART(Figure 3). The proportion of preterm births decreased from 45% in the naïve analysis 
to 30%, when 60% of the variance in gestational age was considered due to measurement 
error. For both SGA and preterm birth, performing multiple imputation alone dramatically 
improved precision, compared with the naïve-analysis. Additionally performing multiple 
overimputation appropriately propagated uncertainty about the true value of gestational age 
through to final confidence intervals, slightly decreasing precision from the multiple 
imputation analysis. For both preterm birth and SGA, results were similar across sensitivity 
analyses.
Discussion
The goal of our analysis was to demonstrate the use of multiple overimputation and to assess 
whether associations between duration of combination ART and pregnancy outcomes were 
sensitive to assumptions about measurement error in gestational age. We found no evidence 
of an increased risk of SGA across a range of assumptions about measurement error in 
gestational age. This finding aligns with some previous evidence that combination ART use 
during pregnancy does not appear to increase the risk of fetal growth restriction.(37) More 
recent work from animal models suggest that protease inhibitor (PI)-based combination ART 
may reduce progesterone levels during pregnancy, which could affect fetal growth.(26) In 
Zambia, PI-based combination ART is reserved for second line therapy. All women in our 
analysis were on first line therapy, which may explain why we did not observe an association 
between duration of combination ART and SGA.
Associations between duration of combination ART and preterm birth in our analysis were 
sensitive to assumptions about measurement error in gestational age. In the naive and 
multiple imputation analyses, there was no evidence that duration of combination ART 
increased the risk of preterm birth. However, when measurement error was additionally 
considered, the risk of preterm birth for 9-32 weeks of combination ART increased as the 
amount of measurement error assumed increased. An association between combination ART 
use early during pregnancy (consistent with longer duration of therapy) and preterm birth 
has been reported in observational studies. (38, 39) In a recent randomized controlled trial, 
PI-based combination ART was found to increase the risk of preterm birth.(40)
In our analysis, a priori we assumed that the measurement error in gestational age was likely 
to account for approximately 30% of its variance. However, point estimates were slightly 
closer to those observed in other studies (38, 39) when 60% variance due to measurement 
error was assumed. This suggests that the proportion of the variance due to measurement 
error in gestational age may have been closer to 60%. Interestingly, our results did not 
change meaningfully when only random measurement error was assumed (despite clear 
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evidence of non-random measurement error). However, point estimates when only random 
measurement error was assumed were close to those seen in the multiple imputation 
analysis, suggesting that changes in effect estimates were largely driven by the substantial 
amount of missing data.
Assumptions and Limitations
Multiple overimputation rests on several assumptions, of which we examine the plausibility 
in our data. It assumes that measurement error and missing data depend only on observed 
data.(22) In our data, error in gestational age was largely considered to be due to patient's 
memory or recording errors by staff. Such errors in memory or recording are unlikely to 
depend on unmeasured factors. Nevertheless, there may be important predictors of 
measurement error in gestational age that were not measured, such as whether a woman 
experienced irregular menstrual cycles. However, in our population of HIV infected women 
where breastfeeding is routine, irregular menstrual cycles may be the norm.
Multiple overimputation also assumes that measurement error is random, conditional on 
observed covariates and the observation-level prior (wi + ai). In our population, 
measurement error in gestational age was primarily due to errors in recording or 
remembering LMP dates. Such measurement error is likely to be normal, conditional on 
observed gestational age. Some groups of women, such as those with irregular menstrual 
cycles, may be more likely to have a mismeasured value of gestational age. However, it is 
unlikely that women with irregular menstrual cycles are more likely to deliver at a particular 
gestational age (e.g. conditional on observed gestational age, measurement error is random).
Additionally, multiple overimputation assumes that observation-level priors and the 
imputation model are correctly specified.(22) We evaluated the robustness of our results to 
this assumption in several ways: 1) by varying the proportion of variance due to 
measurement error assumed, 2) in sensitivity analyses assuming only random measurement 
error and 3) by varying the specification of imputation model, all with similar results.
Finally, our analysis assumed that a reference curve based on a HIV-uninfected population 
correctly defined SGA in a population of HIV-infected women. Such an approach assumes 
that differences between observed and expected gestational age are due to measurement 
error only, and not HIV status. While reference curves for HIV-infected women are not 
available, similar patterns of measurement error in gestational age were observed in our data 
when both HIV-infected and uninfected women were considered.
Measurement error is rarely addressed in epidemiologic studies, yet the ability to measure 
variables correctly is fundamental to making inference.(41) In our analysis of duration of 
combination ART before delivery and its associations with SGA and preterm birth we 
developed a multiple overimputation model to address missing data and measurement error 
in gestational age, using LMP and fundal height measurements. An association between 
longer duration of combination ART and preterm birth was observed only after accounting 
for missing data and measurement error. Our findings suggest that the measurement error in 
gestational age may have implications for associations between duration of combination 
ART and pregnancy outcomes, particularly preterm birth. As lifelong combination ART is 
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scaled up to all HIV-infected pregnant women, routinely collected clinical data will likely 
continue to play an important role in monitoring the relationship between combination ART 
use and pregnancy outcomes. Future analyses examining these associations should consider 
the use of multiple overimputation to address measurement error in gestational age.
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Figure 1. 
Observed versus expected gestational age of 9,529 HIV-infected women in Lusaka, Zambia 
2009-2013. The X-axis indicates the value of gestational age (weeks) observed in the data. 
To calculate expected values of gestational age (Y-axis), we compared each week of 
gestational age at birth to a reference curve adjusted to a Zambian population and found the 
smallest absolute difference in birthweight among reference curve values. The dotted line 
indicates expected gestational age based on mean birthweight and the dashed lines indicate 
expected values based on the 25th and 75th percentiles of birthweight. The diagonal line 
indicates perfect agreement between observed and expected values. The divergence of the 
dotted and dashed lines from the line of agreement at gestational ages <37 weeks) suggests 
that the measurement error in at these gestational ages is non-random in the direction of 
gestational age being incorrectly specified as too early. At gestational ages ≥37 weeks, 
measurement error appeared to be more randomly distributed around the line of agreement.
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Figure 2. 
Estimated bias (ai) and observation-level prior mean values (wi + ai) for 9,529 HIV-infected 
women in Lusaka, Zambia 2009-2013. The solid line with dots indicates expected 
gestational age values, based on reference curve mean birthweights. The dashed line 
indicates perfect agreement between observed and expected gestational age values. The 
divergence of expected values from the line of agreement indicates non-random 
measurement error. To correct this non-random measurement error, an estimate of the bias 
was calculated (ai) and added to each observed value of gestational age (wi) to set the mean 
value of the prior for each week of gestational age (solid line). Due to concerns over digit 
preference at earlier gestational ages, we selected values for ai such that observation-level 
prior mean values were between expected values and observed values. To accommodate the 
apparent shift from non-random and to random measurement error across the distribution of 
gestational ages, we selected offset values ranging from 4 to 0 weeks.
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Figure 3. 
Associations between duration of combination ART before delivery with SGA and preterm 
birth (RRs and 95% CIs). All models adjusted for: number of antenatal care visits, age, BMI, 
CD4 count, education, hemoglobin, intermittent presumptive therapy, parity, syphilis 
screening/treatment, tuberculosis status and prior preterm birth. All models are estimated 
using Poisson regression with robust variance estimators.
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Figure 4. 
Gestational age at birth by mean birthweight for 9,529 HIV-infected women in Lusaka, 
Zambia 2009-2013 in the observed, multiply imputed and multiply overimputed data. The 
dashed line indicates reference curve values for gestational age by mean birthweight.
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Table
Sociodemographic and obstetric characteristics of 9,529 HIV-infected women eligible for cART initiation 
during pregnancy in Lusaka, Zambia 2009-2013.
Characteristic
Small for gestational age a
N(%) or Median (IQR)
Normal for gestational age a
N(%) or Median (IQR)
Missing Data
N (%)
N=583 (8) N=6,814 (92) N=9,529
Age 27 (23, 31) 27 (23, 31) 17 (0)
Education 1,201 (13)
    Primary or None 252 (50) 2,720 (46)
    Secondary or higher 255 (50) 3,223 (54)
Parity 903 (10)
    0 145 (27) 1,150 (19)
    1 140 (26) 1,571 (24)
    2 108 (20) 1,517 (25)
    2+ 146 (27) 1,912 (31)
BMI 23 (21, 25) 23 (22, 25) 3,130(33)
CD4 count 230 (156, 286) 239 (168, 297) 0 (0)
Hemoglobin 11 (10, 12) 11 (10, 12) 759 (8)
Syphilis screening 0 (0)
    Non-reactive 372 (64) 4,246 (62)
    Reactive 28 (5) 331 (5)
    Not tested 183 (31) 2,237 (33)
Tuberculosis 2,590 (27)
    No 410 (97) 4,380 (97)
    Yes 14 (3) 137 (3)
IPT b for Malaria 0 (0)
    None 154 (26) 1,701 (25)
    1 dose SP 301 (52) 3,543 (52)
    2 doses SP 82 (14) 1,086 (16)
    3 doses SP 46 (8) 478 (7)
Number of antenatal care visits 0 (0)
    1 298 (51) 3,607 (54)
    2 141 (24) 1,734 (26)
    3 97 (17) 978 (14)
    ≥4 47 (8) 432 (6)
Previous preterm birth 0 (0)
    No 564 (96.7) 6,602 (96.9)
    Yes 19 (3.3) 212 (3.1)
BMI = body mass index; IPT: intermittent presumptive therapy; SP: sulfadoxine-pyrmethamine
a
Missing outcomes: SGA 2,132 (22.4%), preterm birth 1,399 (14.7%).
b
cART : combination antiretroviral therapy
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